A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors.

Saved in:

Bibliographic Details
Title:	A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors.
Authors:	Kebenko M; Department of Oncology/Hematology, Bone Marrow Transplantation and Section Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Goebeler ME; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany., Wolf M; Clinic Kassel, Kassel, Germany., Hasenburg A; Department of Gynecology, Johannes Gutenberg University Medical Center, Mainz, Germany., Seggewiss-Bernhardt R; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany., Ritter B; Clinic Kassel, Kassel, Germany., Rautenberg B; Department of Gynecology, Johannes Gutenberg University Medical Center, Mainz, Germany., Atanackovic D; Department of Oncology/Hematology, Bone Marrow Transplantation and Section Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Kratzer A; Amgen Research (Munich) GmbH, Munich, Germany., Rottman JB; Amgen Inc., Thousand Oaks, CA, USA., Friedrich M; Amgen Research (Munich) GmbH, Munich, Germany., Vieser E; Amgen Research (Munich) GmbH, Munich, Germany., Elm S; Amgen Research (Munich) GmbH, Munich, Germany., Patzak I; Amgen Research (Munich) GmbH, Munich, Germany., Wessiepe D; Metronomia Clinical Research GmbH, Munich, Germany., Stienen S; Amgen Research (Munich) GmbH, Munich, Germany., Fiedler W; Department of Oncology/Hematology, Bone Marrow Transplantation and Section Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Source:	Oncoimmunology [Oncoimmunology] 2018 Apr 18; Vol. 7 (8), pp. e1450710. Date of Electronic Publication: 2018 Apr 18 (Print Publication: 2018).
Publication Type:	Journal Article; Research Support, Non-U.S. Gov't
Journal Info:	Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: eCollection Cited Medium: Print ISSN: 2162-4011 (Print) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: PubMed not MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	2162-4011
DOI:	10.1080/2162402X.2018.1450710